Neonatal Meningitis (Streptococcus agalactiae - Group B Streptococcus)

Overview


Plain-Language Overview

Neonatal meningitis is a serious infection that affects the protective membranes covering a newborn baby's brain and spinal cord. It is most commonly caused by the bacteria Group B Streptococcus (GBS), which can be passed from mother to baby during childbirth. This infection primarily involves the central nervous system and can lead to symptoms such as fever, irritability, poor feeding, and difficulty breathing. If untreated, it can cause severe complications including brain damage, hearing loss, or even death. Early recognition and diagnosis are critical to managing this condition effectively. The infection disrupts normal brain function by causing inflammation and swelling in the meninges, the thin layers surrounding the brain and spinal cord.

Clinical Definition

Neonatal meningitis is an infection characterized by inflammation of the meninges in newborns, typically occurring within the first 28 days of life. The most common causative agent is Streptococcus agalactiae (Group B Streptococcus), which colonizes the maternal genital tract and is transmitted vertically during delivery. The pathogenesis involves bacterial invasion of the bloodstream followed by crossing the blood-brain barrier, leading to meningeal inflammation. Clinically, it presents with nonspecific signs such as fever, lethargy, poor feeding, and respiratory distress. The condition is a major cause of neonatal morbidity and mortality worldwide. Diagnosis and prompt treatment are essential to prevent long-term neurological sequelae such as hydrocephalus, seizures, and developmental delay.

Inciting Event

  • Vertical transmission of Streptococcus agalactiae during passage through the birth canal.

  • Ascending infection following premature rupture of membranes or prolonged labor.

  • Inadequate intrapartum antibiotic prophylaxis in colonized mothers allows bacterial transmission.

  • Intra-amniotic infection leading to fetal exposure to bacteria in utero.

Latency Period

  • Early-onset neonatal meningitis typically presents within the first 24-72 hours after birth.

  • Late-onset disease can occur from 7 days to 3 months of age, often from nosocomial or community sources.

  • Symptoms usually develop rapidly after bacterial exposure due to rapid bacterial proliferation.

Diagnostic Delay

  • Nonspecific early symptoms such as irritability and poor feeding delay recognition.

  • Overlap with other neonatal infections like sepsis or pneumonia complicates diagnosis.

  • Lack of maternal screening or unknown colonization status delays suspicion.

  • Subtle or absent fever in neonates can lead to underestimation of severity.

Clinical Presentation


Signs & Symptoms

  • Fever or hypothermia in neonates with meningitis

  • Irritability and high-pitched crying

  • Apnea or respiratory distress

  • Seizures indicating CNS involvement

  • Poor feeding and vomiting

  • Lethargy or decreased responsiveness

History of Present Illness

  • Poor feeding, lethargy, and irritability are common initial symptoms.

  • Fever or hypothermia may be present but is often inconsistent in neonates.

  • Respiratory distress and apnea can develop as infection progresses.

  • Seizures and bulging fontanelle indicate advanced meningeal involvement.

  • Rapid clinical deterioration with signs of sepsis and shock may occur.

Past Medical History

  • Maternal Group B Streptococcus colonization or previous infant with GBS disease increases risk.

  • Premature rupture of membranes or prolonged labor history is relevant.

  • Preterm birth or low birth weight history predisposes to severe infection.

  • Lack of intrapartum antibiotic prophylaxis in prior deliveries is significant.

Family History

  • There is no strong heritable predisposition to neonatal meningitis caused by Group B Streptococcus.

  • Family history is generally not contributory to risk or presentation.

  • Rare immunodeficiency syndromes in family may increase susceptibility but are uncommon.

Physical Exam Findings

  • Bulging fontanelle indicating increased intracranial pressure in neonates

  • Poor feeding and lethargy reflecting systemic illness

  • Hypotonia and decreased spontaneous movements

  • Seizures may be observed as focal or generalized convulsions

  • Respiratory distress due to systemic infection or sepsis

Diagnostic Workup


Diagnostic Criteria

Diagnosis of neonatal meningitis relies on cerebrospinal fluid (CSF) analysis obtained via lumbar puncture, showing elevated white blood cell count, decreased glucose, and increased protein levels. Identification of Group B Streptococcus by CSF culture or Gram stain confirms the diagnosis. Blood cultures are also important for detecting bacteremia. Clinical signs combined with laboratory findings and positive microbiological tests establish the diagnosis. Neuroimaging may be used to assess complications but is not diagnostic.

Pathophysiology


Key Mechanisms

  • Hematogenous spread of Streptococcus agalactiae from maternal genital tract to neonate causes meningeal infection.

  • Bacterial invasion of the blood-brain barrier leads to inflammation of the meninges and cerebrospinal fluid (CSF) pleocytosis.

  • Neutrophilic infiltration and release of proinflammatory cytokines cause meningeal edema and increased intracranial pressure.

  • Capsular polysaccharide of Group B Streptococcus enables immune evasion and promotes bacterial survival in the bloodstream.

  • Endotoxin-mediated endothelial damage contributes to blood-brain barrier disruption and neuronal injury.

InvolvementDetails
Organs

Brain is the primary organ affected, with inflammation causing neuronal injury, increased intracranial pressure, and potential long-term neurological sequelae.

Kidneys require monitoring during treatment due to potential nephrotoxicity from aminoglycoside antibiotics.

Tissues

Meninges are inflamed in neonatal meningitis, leading to characteristic clinical signs such as neck stiffness and irritability.

Choroid plexus tissue may be involved as a site of bacterial entry and inflammation within the CNS.

Cells

Neutrophils are the primary immune cells infiltrating the cerebrospinal fluid, mediating bacterial clearance and inflammation.

Microglia act as resident CNS macrophages, contributing to the inflammatory response and phagocytosis of bacteria.

Endothelial cells of the blood-brain barrier become activated and more permeable, facilitating leukocyte migration into the CNS.

Chemical Mediators

Interleukin-1 (IL-1) is a pro-inflammatory cytokine elevated in cerebrospinal fluid, promoting fever and leukocyte recruitment.

Tumor necrosis factor-alpha (TNF-α) amplifies the inflammatory response and contributes to blood-brain barrier disruption.

Prostaglandins mediate fever and vasodilation during the inflammatory process in meningitis.

Treatments


Pharmacological Treatments

  • Ampicillin

    • Mechanism:
      • Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis.

    • Side effects:
      • Allergic reactions

      • Diarrhea

      • Rash

    • Clinical role:
      • First-line

  • Gentamicin

    • Mechanism:
      • Binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.

    • Side effects:
      • Nephrotoxicity

      • Ototoxicity

      • Neuromuscular blockade

    • Clinical role:
      • First-line

  • Cefotaxime

    • Mechanism:
      • Third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

    • Side effects:
      • Hypersensitivity reactions

      • Diarrhea

      • Elevated liver enzymes

    • Clinical role:
      • Alternative first-line

Non-pharmacological Treatments

  • Supportive care including maintenance of airway, breathing, and circulation is essential in managing neonatal meningitis.

  • Intravenous fluid management to maintain hydration and electrolyte balance is critical during treatment.

  • Monitoring and management of intracranial pressure may be necessary in severe cases.

Prevention


Pharmacological Prevention

  • Intrapartum intravenous penicillin or ampicillin prophylaxis to GBS-colonized mothers

  • Use of ampicillin and gentamicin empirically in neonates at risk

  • Prompt initiation of targeted antibiotics upon diagnosis to prevent progression

Non-pharmacological Prevention

  • Universal screening of pregnant women for GBS colonization at 35-37 weeks gestation

  • Proper aseptic technique during delivery and neonatal care

  • Early identification and monitoring of neonates born to GBS-positive mothers

  • Avoidance of prolonged rupture of membranes to reduce vertical transmission

Outcome & Complications


Complications

  • Septic shock due to systemic infection

  • Hydrocephalus from impaired CSF flow

  • Brain abscess or ventriculitis

  • Disseminated intravascular coagulation (DIC)

  • Multiorgan failure in severe cases

Short-term Sequelae Long-term Sequelae
  • Persistent seizures despite treatment

  • Respiratory failure requiring mechanical ventilation

  • Electrolyte imbalances from systemic illness

  • Intracranial hemorrhage secondary to inflammation

  • Sensorineural hearing loss is a common permanent complication

  • Neurodevelopmental delay including cognitive and motor impairments

  • Cerebral palsy due to brain injury

  • Visual impairment from optic nerve involvement

  • Epilepsy developing after acute meningitis

Differential Diagnoses


Neonatal Meningitis (Streptococcus agalactiae - Group B Streptococcus) versus Neonatal Meningitis (Escherichia coli)

Neonatal Meningitis (Streptococcus agalactiae - Group B Streptococcus)

Neonatal Meningitis (Escherichia coli)

Gram-positive cocci in chains, beta-hemolytic, group B antigen positive

Gram-negative rod commonly causing neonatal meningitis, especially in preterm infants

Often associated with maternal vaginal colonization by group B streptococcus

Often associated with maternal urinary tract infections or prolonged rupture of membranes

Typically sensitive to penicillin and ampicillin-based regimens

May require addition of aminoglycosides due to resistance patterns

Neonatal Meningitis (Streptococcus agalactiae - Group B Streptococcus) versus Neonatal Meningitis (Listeria monocytogenes)

Neonatal Meningitis (Streptococcus agalactiae - Group B Streptococcus)

Neonatal Meningitis (Listeria monocytogenes)

Gram-positive cocci in chains, extracellular pathogen

Gram-positive rod, facultative intracellular pathogen

Associated with maternal vaginal colonization without specific food exposure

Associated with maternal ingestion of unpasteurized dairy or contaminated food

Typically presents within first week of life

Can present in early or late neonatal period, often within first week

Usually treated with ampicillin alone or with gentamicin

Requires ampicillin plus gentamicin for effective treatment

Neonatal Meningitis (Streptococcus agalactiae - Group B Streptococcus) versus Neonatal Meningitis (Herpes Simplex Virus)

Neonatal Meningitis (Streptococcus agalactiae - Group B Streptococcus)

Neonatal Meningitis (Herpes Simplex Virus)

Gram-positive bacterial cocci causing meningitis

Double-stranded DNA virus causing meningoencephalitis

Positive bacterial culture or antigen test for group B streptococcus

Positive PCR for viral DNA in cerebrospinal fluid

Presents with fever, irritability, and nonspecific signs of bacterial meningitis

Often presents with seizures and focal neurological signs

Neonatal Meningitis (Streptococcus agalactiae - Group B Streptococcus) versus Neonatal Meningitis (Klebsiella species)

Neonatal Meningitis (Streptococcus agalactiae - Group B Streptococcus)

Neonatal Meningitis (Klebsiella species)

Gram-positive cocci in chains, sensitive to beta-lactams

Gram-negative encapsulated rod, often multidrug resistant

Often community-acquired from maternal colonization

More common in hospital-acquired infections or NICU settings

Responds well to ampicillin and gentamicin

May require carbapenems due to extended-spectrum beta-lactamase production

Medical Disclaimer: The content on this site is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you think you may be experiencing a medical emergency, call 911 or your local emergency number immediately. Always consult a licensed healthcare professional with questions about a medical condition.

Artificial Intelligence Use: Portions of this site’s content were generated or assisted by AI and reviewed by Erik Romano, MD; however, errors or omissions may occur.

USMLE® is a registered trademark of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). Doctogenic and Roscoe & Romano are not affiliated with, sponsored by, or endorsed by the USMLE, FSMB, or NBME. Neither FSMB nor NBME has reviewed or approved this content. "USMLE Step 1" and "USMLE Step 2 CK" are used only to identify the relevant examinations.